stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Current ratio
Travere Therapeutics, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 3.0×, up 0.3× from fiscal 2025 (2.7×). Over the past ten years it has ranged from 2.1× (fiscal 2024) to 4.7× (fiscal 2018); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 5.0× and in line with the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.7× | 31.83% |
| FY2024 | 2.1× | (40.13%) |
| FY2023 | 3.5× | 1.32% |
| FY2022 | 3.4× | (27.15%) |
| FY2021 | 4.7× | 6.04% |
| FY2020 | 4.4× | (1.47%) |
| FY2019 | 4.5× | (5.12%) |
| FY2018 | 4.7× | 24.58% |
| FY2017 | 3.8× | (4.72%) |
| FY2016 | 4.0× | 14.99% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.0× | (25.77%) |
| Jun 2026 | 4.0× | 29.25% |
| Mar 2026 | 3.1× | 14.40% |
| Dec 2025 | 2.7× | (0.40%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| MANE Veradermics Incorporated compare | 70.5× |
| DNTH Dianthus Therapeutics, Inc. compare | 30.0× |
| CRSP CRISPR Therapeutics AG compare | 16.2× |
| COGT Cogent Biosciences, Inc. compare | 13.6× |
| EWTX Edgewise Therapeutics, Inc. compare | 12.3× |
| ERAS Erasca, Inc. compare | 8.3× |
| DFTX Definium Therapeutics, Inc. compare | 6.9× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 3.0× |
| TVTX Travere Therapeutics, Inc. | 3.0× |
| Biotechnology industry median | 5.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement